Article

Ezh2 Inhibitors Reverse Resistance to Gefitinib in Primary Egfr Wild-type Lung Cancer Cells

2020-06-11

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC) is the most common type of lung cancer. Traditional anticancer therapies involving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKIs) have been proven beneficial in the treatment of patients with EGFR mutations. However, patients wit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8d472e6a-d2c0-5872-96b0-101c1428f3e5
DOI: 10.21203/rs.3.rs-33892/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ezh2 Inhibitors Reverse Resistance to Gefitinib in Primary Egfr Wild-type Lung Cancer CellsDOI 10.21203/rs.3.rs-33892/v1Read

EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axisSemantic proximity Read

EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltratesSemantic proximity Read

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).Semantic proximity Read

NRF1 Predominantly Causes EZH2 Overexpression in Cancer CellsSemantic proximity Read

Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancerSemantic proximity Read

High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.Semantic proximity Read

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read

β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2Semantic proximity Read

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.Semantic proximity Read

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read

PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibitionSemantic proximity Read

Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation<strong> </strong>Semantic proximity Read